Honolulu, HI (PRWEB) January 29, 2013
NeuroMetrix, a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, will supply at no cost, its NC-stat DPNCheck technology for program use in testing and monitoring patients for diabetic neuropathy. NC-stat DPNCheck is a non-invasive, fast, accurate and quantitative test for systemic neuropathy, including diabetic neuropathy. The test can be performed at the point-of-care in less than a minute. Results are immediate and provide definitive diagnosis and severity thereby helping guide patient care.
The CMMI grant, totaling $4 million, will be used to cover 600 type 1 and type 2 patients with diabetes over a three year period and will be conducted in partnership with AlohaCare, Hawaii’s largest safety-net health plan. The project combines mHealth tools, specialized care coordination and social media to help low-income people with diabetes in Hawaii improve their health.
The FirstVitals program is designed around the use of Bluetooth-enabled blood glucose meters, internet-connected tablets and proprietary home-based imaging and sensing devices to track key clinical information and facilitate easy communication with the patient to enable early detection and prevention of complications.
The initial step in the program is to identify people with diabetes who are at elevated risk for neuropathy and foot disease via medical claims data supplied by the health plan, and through screening all diabetic AlohaCare members with the NC-stat DPNCheck device for neuropathy.
David Goodman, MD, MSE, FirstVitals co-founder and Chief Medical Officer said, “We are very pleased that NeuroMetrix is supporting this program with DPNCheck technology. We can obtain an objective and reproducible assessment of neuropathy in less than a minute during a routine clinic visit. This technology will allow us to easily risk-adjust patients based on the presence of neuropathy, a key biomarker in the progression of diabetic complications and costs of care. It may also allow us to identify patients with early neuropathy before they develop clinical numbness, potentially providing an opportunity to slow the progression of neuropathy through more aggressive lifestyle interventions.”
“This study’s focus on the early identification and management of the complications of diabetes make it a natural fit for NC-stat DPNCheck, “ said Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. “We are pleased to have the opportunity to provide support.”
FirstVitals, founded in 2010 to deliver scalable health, wellness and disease management programs based on proprietary technology-enabled services, is planning to deploy its unique diabetes intervention which, in addition to improving glycemic control, will incorporate technologies that can enable early identification of patients at risk of diabetes-related complications early enough to prevent, such as foot ulcers.
FirstVitals is focused on foot care, because diabetic foot ulcers are one of the most feared and expensive diabetic complications. Diabetic foot ulcers are the leading cause of lower extremity amputations in the United States and diabetic foot problems are responsible for 20% of all costs of care related to diabetes. For more information, please visit http://www.firstvitals.com/cms.
NeuroMetrix is an innovative medical device company that develops and markets home use and point-of-care devices for the treatment and management of diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation, cause disabling chronic pain, and increase the risk of falling in the elderly. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company’s products are used by physicians and managed care organizations to optimize patient care and reduce healthcare costs. The company markets the NC-stat® DPNCheck™ device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. The company also markets the SENSUS™ Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy. The company has additional therapeutic products in its pipeline. For more information, please visit http://www.neurometrix.com.
FirstVitals Contact: Ernie Lee
“The project described is supported by Grant Number 1C1CMS331072 from the Department of Health and Human Services, Centers for Medicare and Medicaid Services.” The contents of this news release are solely the responsibility of the authors and have not been approved by the Department of Health and Human Services, Centers for Medicare and Medicaid Services.”